VolitionRx CEO: ease of use & early stage detection key to cancer blood test


*** do blood tests detect cancer ***

Cameron Reynolds, chief executive of VolitionRx (NYSE:VNRX), describes company’s cancer blood test as revolutionary as a method of detecting cancer in the early stages and could prove critical for the improvement of patients' survival rates.
Today, Volition Rx reported over 90% accuracy for its new and affordable cancer blood test in a study into colorectal cancer in Belgium.
Its NuQ test identified 23 colorectal cancer sufferers out 121 patients tested.

Video credits to the YouTube channel owner


VolitionRx CEO: ease of use & early stage detection key to cancer blood test

Leave a Reply

Your email address will not be published. Required fields are marked *

log in

reset password

Back to
log in